CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 15 No. 9
Pages: 1  2  3  
Next
Clinical Trials Referral Resource 

Investigator-Initiated Health-Related Quality-of-Life Research

By Julia H. Rowland, PhD, Claudette G. Varricchio, DSN, RN, FAAN, Edward L. Trimble, MD, MPH, and Robert E. Gore-Langton, PhD
National Cancer Institute, Bethesda, Maryland

| September 1, 2001

In part I of this series, we identified currently active clinical trials that include health-related quality-of-life (HRQOL) outcomes as a primary or secondary objective of the overall study (Trimble EL et al: ONCOLOGY 15:601-611, 2001). The goal of this list was to increase the clinician’s awareness of, and referral of potentially eligible patients to ongoing trials in this area.

Clinical Trials Referral Resource is designed to serve as a ready reference for oncologists to help identify clinical trials that might be suitable for their patients. We hope it will also enhance accrual to clinical trials by informing practicing oncologists of ongoing protocols. Currently in the United States less than 10% of eligible adult patients are entered into clinical trials. The result is a delay in answering important therapeutic and scientific questions and disseminating therapeutic advances to the general oncology community.

It should be emphasized that including a specific trial does not imply that it is more important than another trial. Among the criteria for selection are that the trial is addressing an important question and is not expected to close in the immediate future (less than 1 year), and that initial staging or laboratory tests required for patient eligibility are widely practiced and available. Information on other protocols can be accessed via Physician’s Data Query (PDQ).*

We emphasize that this is an attempt to encourage referral of patients to these trials. We are specifically not soliciting additional members for the cooperative groups, nor are we suggesting how practicing oncologists should be treating patients who are not in a study.

This month’s installment of Clinical Trials Referral Resource is devoted to investigator-initiated health-related quality-of-life research.

For patient entry information, see the individual trials.

* PDQ is a comprehensive database service provided by the National Cancer Institute’s International Cancer Information Center and Office of Cancer Communications for retrieval of cancer treatment information, including peer-reviewed statements on treatment options, supportive care, screening, and prevention; and an international clinical trials registry. For more information on PDQ, Internet access is available at http://cancernet.nci.nih.gov/pdqfull.html, or contact the Cancer Information Service offices (1-800-4-CANCER).

In part II, we provide a list of investigator-initiated (R01 type) grants that address interventions to improve HRQOL or health outcomes among patients in active treatment or post-treatment. Because all of these studies are being conducted at specific sites or with previously identified samples, none are "open to accrual" from the general oncology population. (In rare cases, a clinician may be able to enroll a patient because the study’s principal investigator is affiliated with or using patients from their cancer center or local region.)

Our intent in identifying these studies is fourfold. First, as a group they illustrate the direction being taken in HRQOL research that is coming out of the independent investigator community. In contrast to the cancer cooperative groups, the HRQOL focused studies from the investigator-driven community are shifting away from descriptive research. Increasingly, they are proposing (and being funded) to develop and test the efficacy of interventions (both medical and psychosocial/behavioral) to improve HRQOL. Over 50% of the HRQOL-related R01 studies supported by the National Cancer Institute (NCI) now include an intervention component.

Second, by providing information on the different kinds of interventions in development, clinicians and researchers may be stimulated to consider which of these interventions, if successful, might be suitable for phase III testing. One of the major barriers to behavioral/HRQOL research in the oncology setting has been the failure to take successful intervention projects beyond the phase II pilot trial. For example, two meta-analyses have shown that a number of behavioral interventions can improve psychosocial, and in some cases medical, outcomes for treated patients,[1-2] yet phase III studies are not being conducted.

Third, by providing information on these studies, we hope to encourage collaborative research among investigators with common research goals. While fewer subjects are generally needed to evaluate HRQOL-related outcomes than drug treatment outcomes, it is still rare for a single institution alone to be able to accrue sufficient numbers in a timely manner.

Finally, as in part I, by including the specific instruments being evaluated, we hope to provide a resource for investigators who may be looking for appropriate assessment tools. In addition, this information may facilitate a comparison of data already collected with that gathered using the same or similar instruments being used to evaluate different treatments, populations, or follow-up periods.

Fortunately, access to appropriate measurement tools is no longer a significant barrier to advancing HRQOL research. The past decade has seen the growth of an increasing number of well-developed and reliable instruments that permit us to quantify the impact of cancer on patients’ quality, not merely length, of survival.[3-5] It is no longer necessary, or even desirable, for researchers to design assessment measures de novo for a given project. With broader use of common metrics, it will be possible to accurately evaluate the burden of cancer on the larger survivor population as well as our efforts to reduce this burden through clinical research, cancer practice, and health-care policy change.

A key to the many acronyms used in the following listings is provided at the end of this article.

Psychoeducational Intervention

Institution: University of Alberta, Canada
Grant Number: CA79460
Title: Exercise Effects on Quality of Life in Cancer Patients
QOL Intervention: Personalized exercise program to improve physical health and QOL among cancer patients receiving psychosocial counseling
QOL Instruments: FACT (including FS), SWLS, CES-D, TPB Measure, GLTEQ-LSI
Principal Investigator: Kerry Courneya, PhD, (780) 492-1031, kerry.courneya@ualberta.ca

Institution: Brooklyn College, New York
Grant Number: CA68354
Title: Adjustments to Prostate Cancer
QOL Intervention: Facilitated psychoeducational support groups to enhance QOL and adjustment
QOL Instruments: SF-36, CES-D, STAI, POMS-SF, Neugarten’s Measure of Life Satisfaction in the Elderly, DAS, IES, Mishel Uncertainty in Illness Scale, PTGI, UCLA Social Support Scale, Ingram’s Unsupportive Social Interaction Inventory, Lepore’s Social Conflict Scale, LIES, Krantz Health Opinion Survey, Litwin’s Measure of Cancer-Related Problems
Principal Investigator:
Stephen Lepore, PhD, (718) 951-5012, slepore@brooklyn.cuny.edu

Institution: University of California Los Angeles
Grant Number: CA63028
Title: Breast Cancer-Preparing for Survivorship
QOL Intervention: Psychoeducational preparatory interventions to facilitate transition from active treatment to survivorship
QOL Instruments: IES-R, PTGI, PANAS, MHI-17, MOS-SF-36, RAND Mental Health Index, Ladder of Life Scale, CARES, SAQ, Expectations Scale, COPE, EAC, BCPT Symptom Checklist, KPS
Principal Investigator: Patricia Ganz, MD, (310) 206-1404 or (310) 825-3181, Pganz@ucla.edu

Institution: Carnegie Mellon University
Grant Number: CA64711
Title: Adjustment to Breast Cancer Among Young Women
QOL Intervention: Psychoeducational counseling sessions vs low-fat dietary program to enhance QOL among younger women with breast cancer
QOL Instruments: MOS-SF-36, Kansas Inventory of Parental Perceptions, BSI, ABS, IES, DAS, PAIS, FSS, modified Dietary Satisfaction Scale from MDRD, LOT-R, BIS, ISEL, Lubben Social Network Scale, MBSS, COPE, IES, Timko and Janoff-Bulman Illness-Related Expectancies, MUIS-S, Personal Attributes Questionnaire, Duke Severity of Illness Checklist, body-image combined index
Principal Investigator: Michael Scheier, PhD, (412) 268-3791, Fax (412) 268-7810, scheier@cmu.edu

Institution: University of South Florida
Grant Number: CA77307
Title: A Caregiver Intervention to Improve Hospice Outcomes
QOL Intervention: Intervention based on COPE (Creativity, Optimism, Planning, Expert Information) method, friendly visits
QOL Instruments: Caregiver Quality of Life-Cancer, MOS-SF-36, Mastery Scale, HQLI, COPE, MSAS, pain NRS, CAS, DGRIS, DGRRS, Global Improvement Scale, ADL, KPS, SPMSQ
Principal Investigator: Susan McMillan, RN, PhD, (813) 974-9188, smcmilla@hsc.usf.edu

Institution: Stanford University
Grant Number: MH/CA47226-11
Title: Group Therapy for PTSD in Metastatic Breast Cancer
QOL Intervention: Supportive/expressive group therapy plus education
QOL Instruments: CAPS, PCL-C, CES-D, STAI (state version), POMS-SF, SF-12 Health Survey (developed from MOS-SF-36), PTGI, PSOM, SSESSI, IIYL, investigator-developed measure for pain, CDIS, SIE, ZTPI, SCS, YSSI, LSC-R, SASRQ, PDEQ, Nightcap Questionnaire and Ambulatory Device, investigator-developed psychotherapy process measure of Yalom existential concerns
Principal Investigator:
David Spiegel, MD, (650) 723-6421, dspiegel@stanford.edu, website:
http://pstlab.stanford.edu/

Institution: University of Washington
Grant Number: CA78424
Title: Helping the Mother with Breast Cancer Support Her Child
QOL Intervention: "Enhancing Connections Program," a multicomponent educational counseling intervention for mothers and school children during mother’s early-stage breast cancer
QOL Instruments: CES-D, STAI, FPRQ, Relatedness scale, KIDCOPE, RCMAS-What I Think and Feel, CDI, AMMI (including Child’s Cancer Worries Scale and Disenfranchised Grief Scale), CASE-EC, DAS
Principal Investigator: Frances Lewis, RN, MN, PhD, (206) 685-0808, fmlewis@u.washington.edu

Pages: 1  2  3  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

A 48-Year-Old Woman With Irregular Vaginal Bleeding
Brian Morse, MD1 , June 10, 2013

A 48-year-old female presents with complaints of irregular vaginal bleeding and postcoital bleeding. Images from a PET/CT and pelvis MRI reveal characteristic findings. What is your diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
  • ASCO: PD-L1 Antibody Elicits Durable Response in RCC
  • RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • Radiation-Induced Enteritis: Incidence, Mechanisms, and Management
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy